Zai Ding Medicine's revenue for Q2 2026 increased by 11% compared to the previous quarter, and the DLL3 ADC is expected to submit its application for U.S. market approval as early as next year.

Zai Ding Pharmaceuticals released its financial report for the second quarter of 2026, during which the company's total revenue was $106.3 million, compared to $110 million in the same period last year; product revenue was $105.8 million, an 11% quarter-over-quarter increase; and the net loss was $50.8 million, compared to a loss of $40.7 million in the same period last year. As of the end of June, the company had a total of $717.5 million in cash and short-term investments. The company expects to initiate three registration studies before the end of the year, with data on DLL3 ADC in first-line small cell lung cancer to be presented at the ESMO conference in October, and plans to start a registrational Phase III study in the second half of the year; the key Phase III study for second-line and above small cell lung cancer is expected to complete enrollment in the first half of 2027, which is anticipated to support the companys submission of its first application for listing in the United States.